Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation.

Waxman EA, Giasson BI.

J Neurochem. 2010 Apr;113(2):374-88. doi: 10.1111/j.1471-4159.2010.06592.x. Epub 2010 Feb 2.

2.

Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.

Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM.

Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20051-6. doi: 10.1073/pnas.0908005106. Epub 2009 Nov 5.

3.
4.

The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.

Fares MB, Ait-Bouziad N, Dikiy I, Mbefo MK, Jovičić A, Kiely A, Holton JL, Lee SJ, Gitler AD, Eliezer D, Lashuel HA.

Hum Mol Genet. 2014 Sep 1;23(17):4491-509. doi: 10.1093/hmg/ddu165. Epub 2014 Apr 11.

5.

Membrane lipid modification by docosahexaenoic acid (DHA) promotes the formation of α-synuclein inclusion bodies immunopositive for SUMO-1 in oligodendroglial cells after oxidative stress.

Riedel M, Goldbaum O, Wille M, Richter-Landsberg C.

J Mol Neurosci. 2011 Mar;43(3):290-302. doi: 10.1007/s12031-010-9439-5. Epub 2010 Aug 20.

PMID:
20725866
6.

Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated CK2 and cathepsin D.

Takahashi M, Ko LW, Kulathingal J, Jiang P, Sevlever D, Yen SH.

Eur J Neurosci. 2007 Aug;26(4):863-74.

PMID:
17714183
7.

Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.

Lewis KA, Yaeger A, DeMartino GN, Thomas PJ.

J Bioenerg Biomembr. 2010 Feb;42(1):85-95. doi: 10.1007/s10863-009-9258-y. Epub 2010 Feb 11.

8.

The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease.

Wan OW, Chung KK.

PLoS One. 2012;7(6):e38545. doi: 10.1371/journal.pone.0038545. Epub 2012 Jun 12.

9.

Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.

Rutherford NJ, Moore BD, Golde TE, Giasson BI.

J Neurochem. 2014 Dec;131(6):859-67. doi: 10.1111/jnc.12806. Epub 2014 Jul 21.

10.

E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment.

Emmer KL, Waxman EA, Covy JP, Giasson BI.

J Biol Chem. 2011 Oct 7;286(40):35104-18. doi: 10.1074/jbc.M111.247965. Epub 2011 Aug 16.

11.

Contact between the β1 and β2 Segments of α-Synuclein that Inhibits Amyloid Formation.

Shaykhalishahi H, Gauhar A, Wördehoff MM, Grüning CS, Klein AN, Bannach O, Stoldt M, Willbold D, Härd T, Hoyer W.

Angew Chem Int Ed Engl. 2015 Jul 20;54(30):8837-40. doi: 10.1002/anie.201503018. Epub 2015 Jun 26.

PMID:
26119103
12.

Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.

Waxman EA, Giasson BI.

J Neuropathol Exp Neurol. 2008 May;67(5):402-16. doi: 10.1097/NEN.0b013e31816fc995.

13.

Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases.

Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M.

J Biol Chem. 2010 Nov 5;285(45):34885-98. doi: 10.1074/jbc.M110.148460. Epub 2010 Aug 30.

14.

Differential inhibition of α-synuclein oligomeric and fibrillar assembly in parkinson's disease model by cinnamon extract.

Shaltiel-Karyo R, Davidi D, Frenkel-Pinter M, Ovadia M, Segal D, Gazit E.

Biochim Biophys Acta. 2012 Oct;1820(10):1628-35. doi: 10.1016/j.bbagen.2012.04.021. Epub 2012 May 2.

PMID:
22575665
15.

Neuropathology of synuclein aggregates.

Duda JE, Lee VM, Trojanowski JQ.

J Neurosci Res. 2000 Jul 15;61(2):121-7. Review.

PMID:
10878583
16.

Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells.

Ko LW, Ko HH, Lin WL, Kulathingal JG, Yen SH.

J Neuropathol Exp Neurol. 2008 Nov;67(11):1084-96. doi: 10.1097/NEN.0b013e31818c3618.

17.

α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease.

Tomás-Zapico C, Díez-Zaera M, Ferrer I, Gómez-Ramos P, Morán MA, Miras-Portugal MT, Díaz-Hernández M, Lucas JJ.

Hum Mol Genet. 2012 Feb 1;21(3):495-510. doi: 10.1093/hmg/ddr507. Epub 2011 Nov 1.

18.

Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.

Gerard M, Deleersnijder A, Daniëls V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, Debyser Z, Baekelandt V.

J Neurosci. 2010 Feb 17;30(7):2454-63. doi: 10.1523/JNEUROSCI.5983-09.2010.

19.

Assembly of lysine 63-linked ubiquitin conjugates by phosphorylated alpha-synuclein implies Lewy body biogenesis.

Liu C, Fei E, Jia N, Wang H, Tao R, Iwata A, Nukina N, Zhou J, Wang G.

J Biol Chem. 2007 May 11;282(19):14558-66. Epub 2007 Mar 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk